The global market for antibody-drug conjugates (ADCs) is witnessing significant momentum, propelled by advancements in medical research and the rising demand for targeted cancer therapies. ADCs represent a sophisticated class of therapeutics that combine the targeting capabilities of monoclonal antibodies with the cell-killing potency of cytotoxic drugs, offering a promising approach in the treatment of various cancers. The global antibody drug conjugates market in terms of revenue was estimated to be worth $9.7 billion in 2023 and is poised to reach $19.8 billion by 2028, growing at a CAGR of 15.2% from 2023 to 2028. Download the PDF Brochure at https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=122857391 #antibodydrugconjugatesmarket